Scientific deep-dive

Is Cycling Good For Weight Loss? Honest Evidence Review

Cycling burns ~280-840 kcal/h by intensity for a 70 kg adult per the ACSM Compendium. RCTs of structured cycling without diet change produce 1-3% body weight loss over 6-12 months. The real edge over running is joint-friendliness for high-BMI patients.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·13 citations

The honest answer: yes, modestly. Cycling burns ~280 kcal/h at leisurely pace and ~560-840 kcal/h at moderate-to- racing pace for a 70 kg adult per the ACSM Compendium of Physical Activities[1]. RCTs of structured cycling without diet change produce 1-3% body weight loss over 6-12 months — clinically meaningful but modest. Cycling's real edge over running is joint-friendliness and sustainability for high-BMI patients. Cycling at 19-22 km/h moderate effort is ~8 METs, vigorous 22-26 km/h is ~10 METs, and racing >26 km/h is ~12 METs per the canonical Ainsworth Compendium[1]. At these intensities a 70 kg adult burns ~560, ~700, and ~840 kcal/h respectively. The Slentz STRRIDE trial[2] (Archives of Internal Medicine, 2004) randomized 182 overweight adults (120 completed) to 8 months of supervised aerobic training at three doses plus a sedentary control. The high-amount/vigorous group lost 2.9 kg of body mass and 4.8 kg of fat mass; both low-amount groups lost a little weight (0.6–0.9 kg) while the sedentary control group gained 1.0 kg. The Andersen 2000 Copenhagen cohort[7] followed ~30,640 adults and reported that bicycling to work cut mortality risk by roughly 40% after multivariate adjustment, including leisure-time physical activity. The Lusk 2010 Nurses' Health Study II cohort[8] (n=18,414 premenopausal women, 16-year follow-up) found that each 30-min/day increase in bicycling between 1989 and 2005 was associated with ~1.6 kg less weight gain. The honest framing: any structured aerobic exercise produces similar weight loss per equivalent calorie deficit; cycling's edge is adherence — joint-friendly enough to sustain for high-BMI patients, can be done indoors while reading or working, and integrates into commuting in a way running rarely does.

The honest summary

  • Energy cost of cycling by intensity (70 kg adult, ACSM Compendium FDC METs[1]): leisurely (≤16 km/h) ~4 METs ~280 kcal/h; light (16-19 km/h) ~6.8 METs ~480 kcal/h; moderate (19-22 km/h) ~8 METs ~560 kcal/h; vigorous (22-26 km/h) ~10 METs ~700 kcal/h; racing (>26 km/h) ~12 METs ~840 kcal/h. Per-kilometer rule: ~0.3-0.4 kcal/kg/km for outdoor cycling — roughly one-third the per-distance cost of running (~1 kcal/kg/km).
  • STRRIDE 2004 (Slentz, PMID 14718319): 182 overweight adults randomized (120 completed), 8 months of supervised aerobic training at three doses (low-amount/moderate, low-amount/vigorous, high-amount/vigorous), plus sedentary control. The high-amount/vigorous arm lost 2.9 kg of body mass and 4.8 kg of fat mass with no dietary intervention; the control group gained 1.0 kg over the same 8 months. Cleanest direct evidence that structured cycling-inclusive aerobic training produces modest but meaningful weight loss without diet change.
  • Andersen 2000 Copenhagen cohort (PMID 10847255): ~30,640 adults, 14.5-year follow-up. The authors report that bicycling to work cut mortality risk by roughly 40% after multivariate adjustment, including leisure-time physical activity. The first major cohort to identify commuter cycling as an independent mortality-protective behavior.
  • Lusk 2010 Nurses' Health Study II (PMID 20585071): n=18,414 premenopausal women, 16-yr follow-up. Each 30-min/day increase in bicycling between 1989 and 2005 was associated with ~1.6 kg less weight gain. Slow walking was not associated with reduced weight gain; brisk walking and any bicycling were. The signal favored cycling specifically for weight-gain prevention in midlife women.
  • Celis-Morales 2017 UK Biobank (PMID 28424154): n=263,450, 5-yr median follow-up. Cycle commuting associated with HR 0.59 (95% CI 0.42-0.83) for all-cause mortality, 0.48 for cardiovascular mortality, and 0.60 for cancer mortality vs non-active commuting. The strongest single signal in the active-commuting literature.
  • Joint-impact advantage vs running: cycling avoids the repeated ground-strike impact of running, so peak knee loading is much lower. For BMI ≥30 patients, BMI ≥35 patients, patients with prior knee/hip surgery, and patients with early osteoarthritis, cycling is the highest-volume aerobic modality the joints can tolerate. Real edge over running, not marketing.
  • Caloric deficit is still required. The ACSM 2009 threshold[5] for clinically significant weight loss is more than 250 min/wk of moderate-intensity activity (for example, 5 cycling sessions of 50+ min). At 19-22 km/h moderate cycling for 200 min/wk, a 70 kg adult burns ~1,900 kcal/wk — ~0.25 kg/wk theoretical fat loss before compensatory eating offsets part of it. Diet remains the load-bearing lever; cycling is the amplifier and the cardiometabolic-mortality contributor.
  • Magnitude vs GLP-1s: cycling alone produces ~1-3% body weight loss over 6-12 months without diet change. STEP-1 semaglutide[10] produced -14.9% at 68 weeks; SURMOUNT-1 tirzepatide[11] -20.9% at 72 weeks. Cycling is not in the magnitude class of obesity pharmacotherapy. It is the highest-leverage adherent aerobic modality for the high-BMI patient on or off a GLP-1.

Energy cost of cycling by intensity

Cycling caloric burn is the load-bearing number for most weight-loss questions. The mechanistic anchor is the Ainsworth Compendium of Physical Activities[1] (2011 second update, the canonical reference for epidemiology and exercise prescription), which assigns cycling MET values by intensity tier. One MET is approximately 1 kcal/kg/h, so per-hour expenditure scales linearly with body weight.

IntensityMETs50 kg adult (kcal/h)70 kg adult (kcal/h)90 kg adult (kcal/h)
Leisurely (≤16 km/h, ~10 mph)~4~200~280~360
Light (16-19 km/h, 10-12 mph)~6.8~340~480~610
Moderate (19-22 km/h, 12-14 mph)~8~400~560~720
Vigorous (22-26 km/h, 14-16 mph)~10~500~700~900
Racing (>26 km/h, >16 mph)~12~600~840~1080
Stationary 101-125 W (2024 update)~6.8~340~480~610
Stationary 126-150 W (2024 update)~8.0~400~560~720
Stationary 200-229 W (2024 update)~10.8~540~760~970

Two practical implications fall out of the table. First, cycling at conversational pace burns less per hour than running at the same RPE — leisurely cycling (~280 kcal/h for a 70 kg adult) is closer to brisk walking (~280 kcal/h) than to slow jogging (~630 kcal/h). The per-hour caloric edge of cycling shows up at moderate-to- vigorous intensities (~560-840 kcal/h), which require actually pushing the pace, not coasting on a path. Second, stationary cycling at power-meter-defined output burns very predictable calories — in the 2024 Compendium update[12], 101-125 W ≈ 6.8 METs, 126-150 W ≈ 8.0 METs, 200-229 W ≈ 10.8 METs, scaling linearly with body weight. This makes indoor cycling (Peloton, gym stationary, smart trainer with power meter) the most precisely-prescribable aerobic modality for a calorie-target program.

Magnitude comparison vs GLP-1s and other modalities

Magnitude comparison

Total body-weight reduction at trial endpoint — aerobic exercise alone compared with FDA-approved GLP-1 weight-loss medications. Foster-Schubert 2012 exercise-alone postmenopausal arm at 12 months; STEP-1 semaglutide 2.4 mg at 68 wk; SURMOUNT-1 tirzepatide 15 mg at 72 wk. (STRRIDE reported kilograms, not percent: the high-amount arm lost 2.9 kg at 8 months.)[2][4][10][11]

  • Exercise alone (Foster-Schubert, 12 mo)2.4 % TBWL
    Postmenopausal women, 45 min × 5 d/wk moderate aerobic; diet arm lost 8.5%
  • Wegovy — semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
  • Zepbound — tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
Total body-weight reduction at trial endpoint — aerobic exercise alone compared with FDA-approved GLP-1 weight-loss medications. Foster-Schubert 2012 exercise-alone postmenopausal arm at 12 months; STEP-1 semaglutide 2.4 mg at 68 wk; SURMOUNT-1 tirzepatide 15 mg at 72 wk. (STRRIDE reported kilograms, not percent: the high-amount arm lost 2.9 kg at 8 months.)

Cycling is not in the magnitude class of FDA-approved obesity pharmacotherapy. Its evidence-based role is as a deficit-amplifier paired with caloric restriction and a sustainability anchor for adherent activity over years. The Foster-Schubert 12-month data[4] remain the cleanest single-trial demonstration that diet alone produces ~3.5× the weight loss of exercise alone, but diet + exercise produces ~27% more than diet alone. The pattern is unambiguous: dietary change is the load-bearing intervention; cycling amplifies it and independently improves cardiorespiratory fitness, visceral-fat-driven metabolic risk, and (per Andersen[7] and Celis-Morales[9]) all-cause mortality.

Cycling vs running for high-BMI patients

This is where cycling earns its place over running for a large fraction of the weight-loss population. The biomechanics are well-characterized and the clinical implications matter.

Joint loading. Running loads the knee in repeated high-magnitude impacts at every ground-strike, while cycling spreads a much lower load smoothly through the pedal stroke. For a heavier patient covering the same calorie burn, the cumulative joint stress favors cycling by a wide margin.

Clinical patient groups where cycling wins.

  • BMI ≥30 starting weight: running induces knee and hip pain in a substantial fraction of new runners; cycling at the same caloric expenditure is tolerated by nearly all comers. Adherence over months — which is what produces weight loss — favors cycling for this group.
  • BMI ≥35 or ≥40: running is rarely sustainable past 10-15 minutes for most patients in this range due to knee, hip, ankle, and lumbar discomfort plus cardiorespiratory limits. Cycling — particularly recumbent stationary cycling — can extend to 30-60 min sessions at meaningful intensity.
  • Prior knee or hip surgery / replacement: most orthopedic post-operative protocols clear cycling earlier than running, often by months. Cycling is the first aerobic modality cleared in TKA, THA, and ACL rehab.
  • Early osteoarthritis: meta-analytic evidence favors cycling as the lower-symptom-burden aerobic option for OA patients. Running can be tolerated (and is not contraindicated for early OA), but cycling produces fewer pain days per equivalent training stimulus.
  • Pregnancy and postpartum recovery: stationary cycling is routinely permitted into late pregnancy after individualized clearance; running often isn't past the second trimester.
  • Lower-back pain history: recumbent stationary cycling avoids the lumbar-loading pattern of upright cycling and the spinal-impact pattern of running.

For high-BMI patients planning a GLP-1 weight-loss program, cycling is the highest-leverage aerobic modality through the peak weight-loss phase (typically months 4-12) when joint forces drop progressively but cardiorespiratory volume can ramp meaningfully. Running can enter the program later, once BMI has dropped enough that the joint-impact case shifts. Our full pairing protocol is in the exercise-pairing hub for GLP-1 lean-mass preservation.

Stationary bike vs outdoor cycling

For weight loss the choice is mostly about adherence and precision, not physiology. Same calories burn at same power output regardless of whether you're on a road, gravel, or smart trainer.

Stationary cycling — what it's good for. Precisely-prescribable caloric output (the power meter removes the "am I really at moderate intensity" guesswork). Weather-independent — eliminates the November- through-March compliance cliff that hits outdoor cyclists in most US latitudes. Can be done while reading, watching TV, listening to long-form audio, or doing video calls at zone-2 intensity. Recumbent variants accommodate lower-back and balance concerns. Indoor-cycling classes (Peloton, SoulCycle-style, gym group rides) provide adherence-enhancing social structure that outdoor solo riding doesn't. Several of the best fitness apps for weight loss build these guided cycling sessions into a structured, trackable plan.

Outdoor cycling — what it's good for. Commute integration — the strongest mortality signal in the cycling literature comes from commuter cycling (Andersen 2000[7], Celis-Morales 2017[9]), not recreational riding. Built-in NEAT increase from weight-bearing transitions (mounting, dismounting, navigating intersections). Higher caloric burn from wind resistance, terrain variation, and the unavoidable surging of group rides. Lower per-hour boredom for most riders — adherence advantage that compounds over years.

The commute-cycling-specific evidence. Andersen 2000[7] followed ~30,640 Copenhagen adults for 14.5 years and found cycling to work — after adjustment for leisure-time physical activity, smoking, BMI, cholesterol, and other cardiovascular risk factors — independently associated with roughly 40% lower mortality. The 2017 UK Biobank analysis (Celis-Morales[9], n=263,450, 5-year follow-up) reported HR 0.59 for all-cause mortality, 0.48 for cardiovascular mortality, and 0.60 for cancer mortality vs non-active commuting in maximally adjusted models. The active-commuting literature is one of the cleanest cohort-level demonstrations that integrating aerobic activity into the daily structure of life produces bigger downstream benefits than the same total minutes scheduled as recreational exercise.

Pragmatic guidance. If you have a cycle-able commute and tolerate the gear and route logistics, commute cycling captures the strongest mortality signal in the literature and is the highest-yield use of cycling time. If you don't — stationary cycling at home or in a gym is the next-best option, with the advantage that intensity is precisely controllable and adherence is weather-proof. The wrong move is treating outdoor recreational cycling as the default when commute integration is feasible.

RCT evidence: what cycling and aerobic training actually do

STRRIDE 2004 (Slentz, PMID 14718319) — the cleanest dose- response trial

Slentz, Duscha, Johnson, and the Duke STRRIDE investigators (Archives of Internal Medicine, 2004) randomized 182 sedentary, overweight, mildly-dyslipidemic men and women aged 40-65 (120 completed) to 8 months of supervised aerobic training in one of three doses, plus an inactive control. Doses were set as caloric equivalents of walking or jogging:

  • Low-amount / moderate-intensity: the equivalent of ~12 miles/week of walking at 40-55% peak VO2.
  • Low-amount / vigorous-intensity: the equivalent of ~12 miles/week of jogging at 65-80% peak VO2.
  • High-amount / vigorous-intensity: the equivalent of ~20 miles/week of jogging at 65-80% peak VO2.
  • Control: sedentary, no training.

Critically, no dietary intervention was provided — subjects were counseled not to change their diet, and dietary intake did not change in any group. Results at 8 months (body composition by skinfolds):

  • High-amount/vigorous group: 2.9 kg body-mass reduction and 4.8 kg fat-mass reduction.
  • Low-amount/vigorous group: 0.6 kg body-mass and 2.5 kg fat-mass reduction — enough to reverse the weight gain seen in controls, but only a small loss.
  • Low-amount/moderate group: 0.9 kg body-mass and 2.0 kg fat-mass reduction.
  • Control group: body weight increased 1.0 kg over 8 months — the natural drift in this sedentary, mildly-dyslipidemic population.

STRRIDE is the cleanest dose-response demonstration in the cycling-inclusive aerobic-exercise literature. Two takeaways survive translation to clinical practice: (1) you need enough volume. At the lower doses (about 12 miles/week of walking or jogging equivalent), people reversed the drift toward weight gain but lost under 1 kg without diet change. (2) The ceiling without diet change is modest. Even at ~20 miles/week of vigorous training — a substantial time commitment — the 8-month yield was 2.9 kg of body mass.

Willis 2012 STRRIDE AT/RT (PMID 23019316) — aerobic vs resistance head-to-head

The follow-up STRRIDE AT/RT trial[3] (Journal of Applied Physiology, 2012) randomized 196 sedentary overweight or obese adults (119 in the body-composition analysis) to 8 months of aerobic training, resistance training, or combined. Results:

  • Aerobic group: lost 1.76 kg of body mass, and reduced body mass and fat mass more than resistance training alone.
  • Combined aerobic + resistance: not significantly different from aerobic alone for body mass or fat mass, despite double the time commitment.
  • Resistance-only group: gained 0.83 kg of body mass on average but increased lean mass more than aerobic training — the canonical demonstration that resistance training is a body-composition tool, not a scale-weight tool.

For the cycling-specific case, Willis 2012 confirms that aerobic training (cycling-inclusive) is the dominant scale-weight lever in non-pharmacologic exercise programs, and that adding resistance training produces additive lean- mass benefits without compromising fat loss. For GLP-1 patients, the creatine + resistance training evidence layers on top of this aerobic base.

Foster-Schubert 2012 (PMID 21494229) — diet vs exercise hierarchy

Foster-Schubert and colleagues[4] (Obesity (Silver Spring), 2012) randomized 439 overweight-to-obese postmenopausal women to four arms over 12 months: diet alone (10% weight-loss target via calorie restriction), exercise alone (facility-based moderate-intensity aerobic exercise building to 45 min × 5 days/wk), diet + exercise, or control. Results at 12 months:

  • Diet-alone arm: ~8.5% body weight loss.
  • Exercise-alone arm: ~2.4% body weight loss — statistically significant but ~3.5× smaller than the diet effect.
  • Diet + exercise arm: ~10.8% body weight loss — ~27% more than diet alone.
  • Control: ~0.8% body weight loss (regression to the mean + assessment-driven behavior change).

Foster-Schubert remains the load-bearing single trial for the diet-vs-exercise hierarchy: over 12 months, exercise alone produced 2.4% weight loss, diet alone 8.5%, and the combination 10.8%. Cycling-inclusive aerobic exercise is the amplifier, not the primary lever, when scale weight is the outcome measure. When cardiorespiratory fitness, visceral-fat reduction, and all-cause mortality are the outcomes (per Andersen[7] and Celis-Morales[9]), cycling shifts to the primary lever.

Cohort evidence: cycling and long-term outcomes

Andersen 2000 Copenhagen cohort (PMID 10847255) — the canonical mortality signal

Andersen and colleagues[7] (Archives of Internal Medicine, 2000) analyzed the Copenhagen Center for Prospective Population Studies, a ~30,640-person cohort followed for a mean of 14.5 years. The analytic question: does cycling to work, independent of leisure-time physical activity, predict mortality? The answer was unambiguous — after adjustment for age, sex, BMI, blood pressure, blood lipids, smoking, and leisure-time physical activity, cycling to work decreased mortality risk by approximately 40% after multivariate adjustment, as the authors summarize it. Andersen 2000 is the foundational paper for the active-commuting-and-mortality literature.

Lusk 2010 Nurses' Health Study II (PMID 20585071) — cycling and midlife weight gain

Lusk, Mekary, Feskanich, and Willett[8] (Archives of Internal Medicine, 2010) examined bicycling, walking, and weight change among 18,414 premenopausal women in the Nurses' Health Study II over 16 years (1989- 2005). Key findings:

  • Each 30-min/day increase in bicycling between 1989 and 2005 was associated with 1.59 kg less weight gain (95% CI 1.08 to 2.09 kg). Women who went from no bicycling to as little as 5 min/day gained 0.74 kg less than those who stayed non-bikers.
  • The bicycling weight-gain-prevention signal was not seen with slow walking — slow walking was unassociated with reduced weight gain in this cohort.
  • Brisk walking (1.81 kg less per 30 min/day) and bicycling showed similar protective signals for weight maintenance, and the bicycling association was strongest among overweight and obese women.

Lusk 2010 is the strongest single cohort-level signal for cycling specifically (rather than aerobic activity generally) in midlife weight-gain prevention.

Celis-Morales 2017 UK Biobank (PMID 28424154) — the modern large-cohort confirmation

Celis-Morales and colleagues[9] (BMJ, 2017) published the largest active-commuting cohort analysis to date: 263,450 UK Biobank participants followed for a median of 5 years. The headline numbers:

  • Cycle commuting vs non-active commuting: HR 0.59 (95% CI 0.42-0.83) for all-cause mortality.
  • Cardiovascular mortality: HR 0.48 (95% CI 0.25-0.92); cardiovascular disease incidence: HR 0.54 (95% CI 0.33-0.88).
  • Cancer mortality: HR 0.60 (95% CI 0.40-0.90).
  • Mixed mode (cycle + other active): intermediate HRs.
  • Walking commuting: smaller signal — HR 0.73 for cardiovascular disease incidence, no significant all-cause mortality signal.

The Celis-Morales analysis adjusted for sociodemographic, smoking, alcohol, diet, sedentary time, recreational physical activity, and BMI. The cycle-commuting effect survived. The UK Biobank data are sometimes criticized for healthy-volunteer bias — but the within-cohort comparison (cycle commuters vs non-active commuters in the same cohort) is robust to that critique. Combined with the Copenhagen and US-cohort signals, the cycle-commuting mortality protection is one of the most replicated cohort findings in the lifestyle-epidemiology literature.

Cycling + GLP-1 therapy

For patients already on semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda), or orforglipron (Foundayo), cycling is arguably the highest-leverage aerobic modality available. The case rests on three points.

(1) Joint-friendliness during rapid weight loss. GLP-1 patients lose weight steadily over the first year of treatment. During this window the joint forces across the knee and hip are progressively decreasing, but not yet at the lower-impact set point. Cycling permits meaningful aerobic volume (~150-250 min/wk) without the repeated ground-strike impact of running. Adherence during this window is the binding constraint — cycling enables it.

(2) Lean-mass-preservation context. The SURMOUNT-1 DXA substudy[13] documented that about 25% of total weight lost on tirzepatide is lean tissue. Cycling produces cardiorespiratory fitness, glycemic improvement, visceral-fat reduction, and modest lower- extremity muscle-protein-synthesis stimulus — but does NOT produce the hypertrophy or strength-preservation signal of progressive resistance training. The honest pairing on a GLP-1 is cycling for aerobic volume + resistance training for lean-mass preservation + 1.2-1.6 g/kg/day protein. Cycling is the aerobic anchor; resistance training is the lean-mass lever. They are complementary, not substitutable. See our GLP-1 + creatine evidence review for the supplement layer, our exercise pairing hub for the full protocol, and our GLP-1 protein-first eating guide for the dietary layer.

(3) Tolerance during titration. Cycling sessions can be modulated more finely than running during the nausea-dominant phase of GLP-1 titration.Zone-2 stationary cycling at 30-50% peak power is well-tolerated on days when even moderate running is GI-uncomfortable. Patients can preserve aerobic adherence through the titration window with cycling that they couldn't with running. The full GLP-1 side-effect context is in our GLP-1 side-effect Q&A.

When cycling backfires for weight loss

Cycling earns its weight-loss place when used deliberately; the failure modes are predictable and documented.

(1) The post-ride snack trap — over-compensation. A 60-minute moderate ride burns ~560 kcal for a 70 kg adult. A post-ride smoothie + protein bar + sports drink can easily run 800-1,200 kcal. The cyclist-specific norm of "earned" calories — the cultural pattern of post- ride refueling adapted from endurance-athlete behavior — is the single most common reason recreational cyclists fail to lose weight despite logged hours. The refuel can match or exceed what the ride burned, leaving the day net-neutral or net-positive. The honest rule for the weight-loss case: most rides <90 minutes don't require carbohydrate refueling beyond water and electrolytes.

(2) Coffee-shop social rides. The structural norm of group road cycling in the US — easy pace to a coffee stop, easy pace home — typically delivers 1-2 hours of zone-1 activity (~250 kcal/h for the cycling, ~400 kcal for the coffee-and-pastry stop). Net caloric effect is small or positive. This is a fine social pattern; it is not a weight-loss program. The cycling literature signals — STRRIDE high-amount/vigorous arm, Lusk NHS-II added-bicycling cohort — are at moderate-to-vigorous intensities, not social coffee-shop ride pace.

(3) Saddle-time injuries. Padded shorts and proper bike fit aren't optional past ~2 hours/week. Saddle sores, perineal numbness, and pudendal-nerve irritation are the most common adherence-killing complaints in new cyclists. A bike fit (~$100-200 one-time) and quality chamois shorts are the cheapest interventions to keep a new cyclist riding past the 3-month new-habit failure point.

(4) Overuse — IT band, knee tendinopathy, lower back. Cycling is lower-impact than running but not zero-impact. Rapid volume ramps (going from 0 to 150 min/wk in a month) commonly produce IT band syndrome, anterior knee pain, and lower-back tightness. The conservative progression is ~10%/week volume increase — same rule as running.

(5) Treating cycling as a license to skip resistance training. The Willis 2012 STRRIDE AT/RT data[3] are clear: aerobic-only training increased lean mass less than programs that included resistance training, and on a GLP-1 the absence of resistance training accelerates lean-mass loss. Cycling cannot substitute for resistance training in the body- composition case.

(6) E-bikes and motorized assist. Pedal- assist e-bikes increase ride frequency and commute feasibility, both of which are net positives. They also lower per-minute energy expenditure: the 2024 Compendium update[12] lists e-bike riding at ~6.0 METs with light electronic support and ~4.0 METs with high support, vs ~6.8 METs for conventional bicycling to work. For caloric-deficit purposes, log e-bike time at those lower MET assumptions. The mortality-and-adherence benefits of cycling commuting likely transfer; the per-hour caloric burn doesn't.

Threshold guidance: how much cycling for clinically significant weight loss

Two authoritative guidelines define the exercise volume required for clinically significant weight loss.

ACSM 2009 position stand (Donnelly, PMID 19127177)[5]: more than 250 min/wk of moderate-intensity activity has been associated with clinically significant weight loss; 150-250 min/wk prevents weight gain but provides only modest weight loss; and after weight loss, weight maintenance is improved with more than 250 min/wk.

HHS 2018 Physical Activity Guidelines (Piercy, PMID 30418471)[6]: ≥150 min/wk moderate-intensity OR ≥75 min/wk vigorous-intensity aerobic activity, plus muscle-strengthening activities ≥2 days/wk. Additional health benefits accrue beyond the upper bound of the recommended range.

Practical cycling prescriptions for weight loss:

  • Beginner / sedentary baseline: 3 sessions/ wk × 30 min at light-to-moderate intensity (16-19 km/h, ~480 kcal/h for 70 kg adult) = ~90 min/wk, ~720 kcal/wk burn. Below the HHS 150-minute moderate minimum; hold for 4-6 weeks, then progress.
  • Established weight-loss program (with caloric restriction): 4 sessions/wk × 45 min at moderate (19-22 km/h, ~560 kcal/h) = ~180 min/wk, ~1,680 kcal/wk burn. Exceeds HHS minimum, still below the ACSM 250-minute weight-loss threshold.
  • Aggressive aerobic prescription (high-amount STRRIDE arm): 5 sessions/wk × 50 min at vigorous (22-26 km/h, ~700 kcal/h) = ~250 min/wk, ~2,900 kcal/wk burn. Roughly the scale of the STRRIDE high-amount dose, which lost 2.9 kg at 8 months in the trial without diet change.
  • Commute-cycling layer: 5 days × ~20 min each way × light-to-moderate intensity = ~200 min/wk of built-in cycling without scheduling separate workouts. Captures the strongest mortality signal in the literature (Andersen 2000, Celis-Morales 2017).
  • Always pair with resistance training ≥2 days/wk for body-composition and lean-mass-preservation outcomes, per Willis 2012 STRRIDE AT/RT.

Bottom line

  • Cycling burns approximately 280 kcal/h at leisurely pace, 560 kcal/h at moderate (19-22 km/h), 700 kcal/h at vigorous (22-26 km/h), and 840 kcal/h at racing pace (>26 km/h) for a 70 kg adult per the ACSM Compendium[1]. Stationary cycling at 101-125 W is ~6.8 METs (~480 kcal/h for 70 kg); 126-150 W is ~8.0 METs (~560 kcal/h); 200-229 W is ~10.8 METs (~760 kcal/h) in the 2024 Compendium update[12].
  • RCT evidence: STRRIDE high-amount/vigorous aerobic arm[2] lost 2.9 kg at 8 months without diet change; the Willis STRRIDE AT/RT aerobic arm[3] cut body mass more than resistance training alone; Foster-Schubert[4] exercise-alone postmenopausal arm lost ~2.4% at 12 months. Aerobic exercise alone produces 1-3% body weight loss without dietary change — clinically meaningful but modest.
  • Cohort evidence: Andersen 2000 Copenhagen[7] cycle-commuting roughly 40% lower mortality after adjustment; Celis-Morales 2017 UK Biobank[9] cycle-commuting HR 0.59 for all-cause mortality and 0.48 for cardiovascular mortality; Lusk 2010 NHS-II[8] each 30 min/day of added bicycling linked to ~1.6 kg less weight gain over 16 years.
  • Cycling's real edge over running is joint-friendliness and adherence — no repeated ground-strike impact, so peak knee loading is much lower than in running. For BMI ≥30 patients, prior knee or hip surgery, early osteoarthritis, and high-BMI patients in the early phase of a GLP-1 program, cycling is the highest-volume tolerated aerobic modality.
  • Caloric deficit remains the load-bearing lever. Cycling alone produced 2.4% weight loss, diet alone 8.5%, and the combination 10.8% over 12 months in Foster-Schubert 2012[4]. Cycling is the deficit-amplifier and the independent contributor to cardiorespiratory fitness, visceral-fat reduction, and all-cause mortality.
  • For GLP-1 patients: cycling + resistance training ≥2 days/wk + 1.2-1.6 g/kg/day protein is the evidence-aligned pairing. Cycling is the aerobic anchor through the joint- impact-sensitive window of rapid weight loss; resistance training is the lean-mass lever; protein is the substrate.
  • Magnitude check: STEP-1 semaglutide[10] -14.9% at 68 weeks; SURMOUNT-1 tirzepatide[11] -20.9% at 72 weeks. Cycling alone is not in the pharmacotherapy magnitude tier. It is the highest-leverage sustainable aerobic modality for the high-BMI patient population.
  • The verdict: yes, modestly. Cycling earns a place in the weight-loss eating-and-moving plan for nearly every patient — strongest case for high-BMI patients, commute-cyclable city-dwellers, and GLP-1 patients through months 4-12 of titration. The dominant failure modes are post-ride snack over-compensation, social coffee-shop-pace rides treated as workouts, and rapid volume ramps causing knee/IT-band overuse.

Related research

References

  1. 1.Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011. PMID: 21681120.
  2. 2.Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study. Arch Intern Med. 2004. PMID: 14718319.
  3. 3.Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012. PMID: 23019316.
  4. 4.Foster-Schubert KE, Alfano CM, Duggan CR, et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity (Silver Spring). 2012. PMID: 21494229.
  5. 5.Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009. PMID: 19127177.
  6. 6.Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA. 2018. PMID: 30418471.
  7. 7.Andersen LB, Schnohr P, Schroll M, Hein HO. All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Arch Intern Med. 2000. PMID: 10847255.
  8. 8.Lusk AC, Mekary RA, Feskanich D, Willett WC. Bicycle riding, walking, and weight gain in premenopausal women. Arch Intern Med. 2010. PMID: 20585071.
  9. 9.Celis-Morales CA, Lyall DM, Welsh P, et al. Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study. BMJ. 2017. PMID: 28424154.
  10. 10.Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  11. 11.Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  12. 12.Herrmann SD, Willis EA, Ainsworth BE, et al. 2024 Adult Compendium of Physical Activities: A third update of the energy costs of human activities. J Sport Health Sci. 2024. PMID: 38242596.
  13. 13.Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.

Frequently Asked Questions

Yes, modestly. Cycling burns ~280 kcal/h at leisurely pace and ~560-840 kcal/h at moderate-to-racing pace for a 70 kg adult per the ACSM Compendium of Physical Activities. RCTs of structured aerobic exercise (cycling-inclusive) without diet change produce 1-3% body weight loss over 6-12 months — STRRIDE 2004 high-amount/vigorous arm lost 2.9 kg at 8 months; the Willis STRRIDE AT/RT aerobic arm cut body mass more than resistance training alone; Foster-Schubert 2012 exercise-alone postmenopausal arm lost 2.4% at 12 months. Cycling's real edge over running is joint-friendliness — no repeated ground-strike impact, so peak knee loading is much lower — which makes it the highest-volume sustainable aerobic modality for BMI ≥30 patients, post-orthopedic-surgery patients, and GLP-1 patients in the rapid-weight-loss phase. Caloric deficit is still the load-bearing lever; cycling is the amplifier and the independent contributor to cardiorespiratory fitness, visceral-fat reduction, and all-cause mortality.
Per the ACSM Compendium of Physical Activities, a 70 kg adult burns approximately ~280 kcal/h at leisurely pace (≤16 km/h, ~4 METs), ~480 kcal/h at light pace (16-19 km/h, ~6.8 METs), ~560 kcal/h at moderate pace (19-22 km/h, ~8 METs), ~700 kcal/h at vigorous pace (22-26 km/h, ~10 METs), and ~840 kcal/h at racing pace (>26 km/h, ~12 METs). Stationary cycling at power-meter-defined output, per the 2024 Compendium update: 101-125 W ~6.8 METs (~480 kcal/h for 70 kg); 126-150 W ~8.0 METs (~560 kcal/h); 200-229 W ~10.8 METs (~760 kcal/h). Caloric burn scales linearly with body weight: a 50 kg adult burns ~70% of these values; a 90 kg adult burns ~130%.
Per hour, running typically burns more (~600-700 kcal/h at 10 km/h for a 70 kg adult vs ~280-560 kcal/h for cycling at conversational-to-moderate pace). Per session of equivalent calorie burn, the weight-loss effect is approximately equivalent — what matters is total weekly caloric expenditure plus dietary deficit. Cycling's real advantages are (1) joint-friendliness — no repeated ground-strike impact, so peak knee loading is much lower than running; (2) sustainability for high-BMI patients who can't tolerate running volume; (3) precision indoor prescription via power meters; (4) commute integration, which carries the strongest mortality signal in the active-commuting cohort literature (Andersen 2000 Copenhagen: roughly 40% lower mortality for cycling to work; Celis-Morales 2017 UK Biobank HR 0.59). For high-BMI patients, post-orthopedic-surgery patients, and GLP-1 patients in the rapid weight-loss phase, cycling is the higher-leverage choice.
Realistically well under 1 kg per month if cycling is the only change you make, with a wide range depending on intensity. A 30-min ride at moderate pace (19-22 km/h, ~8 METs) burns ~280 kcal for a 70 kg adult; daily for 30 days is ~8,400 kcal, theoretically ~1.1 kg of fat at 7,700 kcal/kg. Compensatory eating and reduced non-exercise activity (NEAT compensation) usually erase part of that deficit, so the net is lower. STRRIDE 2004 (Slentz, PMID 14718319) is the cleanest evidence: 8 months of supervised aerobic training at three doses produced 0.6-2.9 kg of body-mass reduction depending on dose, with no dietary intervention. Pairing cycling with a 500 kcal/day dietary deficit moves the realistic monthly loss to ~2-3 kg.
3-5 days per week is the operative range, with at least one rest day. The ACSM 2009 position stand (Donnelly, PMID 19127177) associates more than 250 min/wk of moderate-intensity activity with clinically significant weight loss; the 2018 HHS Physical Activity Guidelines (Piercy, PMID 30418471) define ≥150 min/wk moderate OR ≥75 min/wk vigorous as the federal minimum. Cycling at 22-26 km/h is vigorous intensity (~10 METs), so 75 min/wk meets the federal minimum. The STRRIDE 2004 high-amount/vigorous arm, calorically equivalent to about 20 miles of jogging a week, lost 2.9 kg at 8 months without diet change. Practical schedule: 4 sessions × 45 min at moderate pace (180 min/wk total), with 2 resistance-training days for lean-mass preservation.
Yes, for calorie burn and weight loss. Same wattage burns same calories regardless of whether you're on a road bike, gravel bike, or smart trainer. Stationary cycling has three specific advantages for weight loss: (1) precisely-prescribable caloric output via the power meter, eliminating the 'am I really at moderate intensity' guesswork; (2) weather-independence, which eliminates the November-through-March compliance cliff that hits outdoor cyclists in most US latitudes; (3) ability to combine with reading, video calls, or audio content at zone-2 intensity. Outdoor cycling carries the strongest mortality signal in the literature — Andersen 2000 Copenhagen (roughly 40% lower mortality for cycle commuters) and Celis-Morales 2017 UK Biobank (HR 0.59) — but this signal is specifically tied to commute-cycling, not recreational outdoor riding. The optimal pattern for most patients: stationary cycling for prescribed workouts, outdoor cycling for commuting if feasible.
Most patients can cycle most days, but daily high-intensity cycling without rest sharply increases overuse-injury risk. The conservative pattern is 4-6 cycling days per week with at least one full rest day, and intensity modulated across the week (2-3 moderate-to-vigorous sessions, 2-3 zone-1-to-zone-2 sessions). Cycling is lower-impact than running, so daily moderate riding is more sustainable than daily running — but IT band syndrome, anterior knee pain, lower-back tightness, and saddle injuries (perineal numbness, pudendal-nerve irritation, saddle sores) are the common adherence-killing complaints in cyclists ramping volume rapidly. The standard ~10%/week volume increase rule applies to cycling as it does to running. Quality bike fit (~$100-200 one-time) and padded shorts past ~2 hours/week of riding are not optional.
Yes — cycling is arguably the highest-leverage aerobic modality for GLP-1 patients, BUT do not substitute it for resistance training in the lean-mass-preservation case. The SURMOUNT-1 DXA substudy showed about 25% of total weight lost on tirzepatide is lean tissue; resistance training (not cycling) is the primary lever to attenuate that loss. Cycling provides cardiorespiratory fitness, glycemic improvement, visceral-fat reduction, and joint-friendly aerobic volume during the rapid weight-loss phase (months 4-12) when peak joint forces are decreasing but not yet at the lower-impact set point. Practical pairing: 3-4 cycling sessions/wk (45-60 min at moderate-to-vigorous intensity) + 2 resistance-training sessions + 1.2-1.6 g/kg/day protein. Avoid high-intensity cycling on the worst nausea days of titration; zone-2 stationary cycling tolerates well when even moderate running doesn't. Patients on insulin or sulfonylureas for type 2 diabetes should monitor for exercise-associated hypoglycemia.
Yes, visceral fat specifically — but no, not via spot reduction. Cycling and other aerobic activity preferentially mobilize visceral (intra-abdominal) fat — the metabolically active fat depot associated with insulin resistance, cardiovascular disease, and type 2 diabetes risk. Visceral fat is more responsive to caloric deficit and aerobic activity than subcutaneous fat. STRRIDE 2004 (Slentz, PMID 14718319) found that all exercise groups reduced abdominal, waist, and hip circumference compared with controls, even at modest body-weight changes. However, the visible 'belly' layer is largely subcutaneous abdominal fat, which responds to systemic caloric deficit, not to doing more cycling or sit-ups locally. Spot reduction of subcutaneous fat by targeted exercise is a myth — fat loss is systemic. The honest framing: cycling is unusually good for the cardiometabolically-relevant visceral fat depot; it is not a 'belly fat burner' in the wellness sense.
Partially. Pedal-assist e-bikes lower per-minute energy expenditure depending on assist level: the 2024 Compendium update lists ~6.0 METs with light electronic support and ~4.0 METs with high support, vs ~6.8 METs for conventional bicycling to work. At high assist, an hour of riding burns roughly the calories of leisurely conventional cycling (~280 kcal/h for a 70 kg adult). E-bikes do increase ride frequency and commute feasibility — both net positives that capture the adherence and mortality-protection signal of cycle commuting. The honest accounting: e-bike commuting probably transfers most of the all-cause mortality benefits documented in the active-commuting literature (Andersen 2000, Celis-Morales 2017) because the cardiovascular and cardiometabolic stimulus of low-to-moderate aerobic activity is preserved; the per-hour caloric burn for weight loss specifically is lower. For weight-loss prescription purposes, log e-bike time at the lower e-bike MET values (~4-6 METs) rather than the moderate-cycling assumption (~8 METs).

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

Pricing Compare

Get started →
7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

Pricing Compare

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

Pricing Compare

Get started →